spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  lupus nephritis 

 HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Apr 2019
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Jul 2017
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2013
Aurinia Appoints Accomplished Biotech and Pharma Industry Veteran, Stephen W. Zaruby, as President & CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Dec 2012
Isotechnika Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Dec 2010
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2010
La Jolla Pharmaceutical Company Provides Update on Search for Clinical Products to In-License or Acquire
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2007
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Sep 2007
Aspreva Provides Update On Lupus Nephritis Development Program
Biopharmaceuticals
 HSMN NewsFeed - 28 Aug 2007
Aspreva and Roche Update CellCept Agreement
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2007
Aspreva announces restructuring designed to drive long-term growth
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2007
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2006
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 30 Mar 2006
Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan(R) in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Feb 2006
FDA Approves Rituxan(R) - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
lupus nephritis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.